{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:35:37Z","timestamp":1792575337282,"version":"4.5.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Anthracyclines increase the risk for congestive heart failure (CHF); however, long-term cumulative incidence and risk factors for CHF after anthracycline therapy are not well defined in population-based studies.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the long-term cumulative incidence of CHF in patients with breast cancer or lymphoma treated with anthracycline therapy compared with healthy controls from the same community.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective population-based case-control study included data from the Rochester Epidemiology Project. Participants included residents of Olmsted County, Minnesota, diagnosed with breast cancer or lymphoma from January 1985 through December 2010 matched for age, sex, and comorbidities with healthy controls, with a final ratio of 1 case to 1.5 controls. Statistical analysis was performed between July 2017 and February 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Cancer treatment and CHF risk factors.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcome was new-onset CHF, as defined by the modified Framingham criteria. Cox proportional hazards regression was used to estimate hazard ratios (HRs) to compare the risk of CHF in participants with cancer vs controls, adjusted for age, sex, diabetes, hypertension, hyperlipidemia, coronary artery disease, obesity, and smoking history.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 2196 individuals were included, with 812 patients with cancer and 1384 participants without cancer. The mean (SD) age was 52.62 (14.56) years and 1704 participants (78%) were female. Median (IQR) follow-up was 8.6 (5.2-13.4) years in the case group vs 12.5 (8.7-17.5) years in the control group. Overall, patients with cancer had higher risk of CHF compared with the control cohort even after adjusting for age, sex, diabetes, hypertension, coronary artery disease, hyperlipidemia, obesity, and smoking status (HR, 2.86 [95% CI, 1.90-4.32]; P<\/jats:italic>\u2009&amp;lt;\u2009.001). After adjusting for the same variables, CHF risk was greater for patients with cancer receiving anthracycline (HR, 3.25 [95% CI, 2.11-5.00]; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and was attenuated and lost statistical significance for patients with cancer not receiving anthracyclines (HR, 1.78 [95% CI, 0.83-3.81]; P<\/jats:italic>\u2009=\u2009.14). Higher cumulative incidence for patients treated with anthracyclines vs comparator cohort was observed at 1 year (1.81% vs 0.09%), 5 years (2.91% vs 0.79%), 10 years (5.36% vs 1.74%), 15 years (7.42% vs 3.18%), and 20 years (10.75% vs 4.98%) (P<\/jats:italic>\u2009&amp;lt;\u2009.001). There were no significant differences in risk of CHF for patients receiving anthracycline at a dose of less than 180 mg\/m2<\/jats:sup> compared with those at a dose of 180 to 250 mg\/m2<\/jats:sup> (HR, 0.54 [95% CI, 0.19-1.51]) or at a dose of more than 250 mg\/m2<\/jats:sup> (HR, 1.23 [95% CI, 0.52-2.91]). At diagnosis, age was an independent risk factor associated with CHF (HR per 10 years, 2.77 [95% CI, 1.99-3.86]; P<\/jats:italic>\u2009&amp;lt;\u2009.001).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this retrospective population-based case-control study, anthracyclines were associated with an increased risk of CHF early during follow-up, and the increased risk persisted over time. The cumulative incidence of CHF in patients with breast cancer or lymphoma treated with anthracyclines at 15 years was more than 2-fold that of the control group.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.54669","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T16:02:17Z","timestamp":1675440137000},"page":"e2254669","source":"Crossref","is-referenced-by-count":102,"title":["Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010"],"prefix":"10.1001","volume":"6","author":[{"given":"Carolyn M.","family":"Larsen","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Garcia Arango","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harika","family":"Dasari","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Arciniegas Calle","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effie","family":"Adjei","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Rico Mesa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tufia C.","family":"Haddad","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Goetz","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector R.","family":"Villarraga","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"issue":"10","key":"zoi221548r1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","article-title":"Cardiotoxicity of anticancer treatments: what the cardiologist needs to know.","volume":"7","author":"Ewer","year":"2010","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"zoi221548r2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11912-016-0514-0","article-title":"Tyrosine kinase inhibitors and vascular toxicity: impetus for a classification system?","volume":"18","author":"Herrmann","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"zoi221548r3","doi-asserted-by":"publisher","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines.","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi221548r4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.echo.2013.07.005","article-title":"Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.","volume":"26","author":"Lancellotti","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"issue":"17","key":"zoi221548r6","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"zoi221548r7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/hrt.2009.173997","article-title":"Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study.","volume":"96","author":"Ho","year":"2010","journal-title":"Heart"},{"issue":"13","key":"zoi221548r8","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.ejca.2015.05.028","article-title":"Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.","volume":"51","author":"Pivot","year":"2015","journal-title":"Eur J Cancer"},{"issue":"11","key":"zoi221548r9","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"22","key":"zoi221548r10","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1002\/cncr.24621","article-title":"Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.","volume":"115","author":"Du","year":"2009","journal-title":"Cancer"},{"issue":"8","key":"zoi221548r11","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1007\/s00520-017-3653-4","article-title":"Functional status and quality of life among breast cancer survivors with heart failure: results of the Medicare Health Outcomes Survey.","volume":"25","author":"Harrison","year":"2017","journal-title":"Support Care Cancer"},{"issue":"24","key":"zoi221548r12","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"zoi221548r13","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/jnci\/djn206","article-title":"New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.","volume":"100","author":"Ryberg","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"zoi221548r14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"8","key":"zoi221548r15","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"zoi221548r16","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity.","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am J Cardiol"},{"issue":"31","key":"zoi221548r17","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","article-title":"Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10203","key":"zoi221548r18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases.","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"zoi221548r19","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma.","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi221548r20","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/MLR.0b013e31825a8c22","article-title":"Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer.","volume":"52","author":"Allen","year":"2014","journal-title":"Med Care"},{"issue":"12","key":"zoi221548r21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S0025-6196(12)60063-9","article-title":"The incidence and prevalence of congestive heart failure in Rochester, Minnesota.","volume":"68","author":"Rodeheffer","year":"1993","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"zoi221548r22","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1093\/ije\/dys195","article-title":"Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system.","volume":"41","author":"St Sauver","year":"2012","journal-title":"Int J Epidemiol"},{"issue":"12","key":"zoi221548r23","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.mayocp.2012.08.012","article-title":"History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population.","volume":"87","author":"Rocca","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"zoi221548r24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.4065\/74.4.330","article-title":"Potential effect of authorization bias on medical record research.","volume":"74","author":"Jacobsen","year":"1999","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"zoi221548r25","first-page":"361","article-title":"The impact of requiring patient authorization for use of data in medical records research.","volume":"47","author":"Yawn","year":"1998","journal-title":"J Fam Pract"},{"issue":"9","key":"zoi221548r26","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/aje\/kwq482","article-title":"Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project.","volume":"173","author":"St Sauver","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"2","key":"zoi221548r27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.mayocp.2011.11.009","article-title":"Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project.","volume":"87","author":"St Sauver","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"21","key":"zoi221548r28","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1161\/01.CIR.98.21.2282","article-title":"Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991.","volume":"98","author":"Senni","year":"1998","journal-title":"Circulation"},{"issue":"5","key":"zoi221548r29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bjh.2018.183.issue-5","article-title":"Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.","volume":"183","author":"Baech","year":"2018","journal-title":"Br J Haematol"},{"issue":"34","key":"zoi221548r30","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1200\/JCO.2017.72.4211","article-title":"Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors.","volume":"35","author":"Salz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi221548r31","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/JCO.21.01736","article-title":"Risk of cardiovascular disease in women with and without breast cancer: the Pathways Heart Study.","volume":"40","author":"Greenlee","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi221548r32","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.v22.9","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).","volume":"22","author":"Celutkiene","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"41","key":"zoi221548r33","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"8","key":"zoi221548r34","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/ajh.v96.8","article-title":"Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era.","volume":"96","author":"Boddicker","year":"2021","journal-title":"Am J Hematol"},{"key":"zoi221548r5","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780190238667.001.0001","volume-title":"Cancer Epidemiology and Prevention","author":"Thun","year":"2017","edition":"4th ed"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2800936\/larsen_2023_oi_221548_1677082688.22046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T16:00:55Z","timestamp":1677859255000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2800936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.54669","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]}}}